In the latest Alzheimer’s research, hidden fat in various parts of the body was shown to be an early warning sign of the common dementia — as long as 20 years prior to symptoms emerging.
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...